Start Date
June 2, 2022
Primary Completion Date
November 25, 2022
Study Completion Date
December 29, 2022
Teduglutide
"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
Placebo
Placebo
Allegheny General Hospital, Pittsburgh
Collaborators (1)
Shire
INDUSTRY
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
OTHER